tirzepatide for the treatment of obstructive sleep apnea In a prespecified secondary analysis SURMOUNT-OSA trial it was found that improves cardiometabolic outcomes in patients with moderate-to-severe OSA and obesity Tirzepatide for Sleep Apnea? The

But only to a limited extent

The core challenge of lasting health is maintenance

In the clinical trial of participants with type 2 diabetes, HbA1c reductions of -1.88% to -2.02% were observed at the 8 mg and 12 mg doses by 24 weeks

GCP : Good Clinical Practices refers to the rules concerning the conduct of clinical trials in humans

The company issued a press release with Rosenstock saying: Orforglipron 12 mg and 36 mg doses outperformed oral semaglutide 7 mg and 14 mg diabetes-related doses on every key endpoint we measured, including A1C and weight loss, with improvements appearing as early as four weeks and sustained throughout the study. But this is not an easy win for Lilly on two counts